Locatelli, Franco <br/><br/>
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.  [electronic resource] 

 -  The Lancet. Haematology  Oct 2018 
 - e450-e461 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2352-3026 
<br/><br/><label>Standard No.: </label>10.1016/S2352-3026(18)30153-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Brentuximab Vedotin<br/>Child<br/>Child, Preschool<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--therapeutic use<br/>Lymphoma, Large-Cell, Anaplastic--drug therapy<br/>Male<br/>Recurrence